Table	Stakeholders?	Activities?
Bacterial Targets	Pharmaceutical companies, researchers, clinicians, companies developing	<u>Pharmaceutical companies</u> : Building connections is problematic, need to find ways to consult them. Clinicians: Mostly listening and learning about their needs
	diagnostics	<u>Diagnostic companies</u> : Invite them to workshops, talk to them
	- At Warwick, mostly Engineers and	There is a gap between basic science and clinical trials.
	Chemists	Design a proposal with the NIHR: The Research Design Service can help
	- The NIHR, who can help bring	researchers design proposals and incorporate patient involvement
Diagnostics	discoveries to the clinical arena.	Join the Academic Health Science Network: a catalyst bringing together NHS and
	Within the NIHR: Research Design	academic organisations, local authorities, the third sector and industry
	Service, Early Contact Team, Research &	Sign up to Clinical Research Network Newsletter: Keep up to date with specialty
	Development Managers	groups and events
	Doctors, nurses, pharmacists, patients,	<u>Use social media</u> : Good news doesn't sell, need a big story. Rebalance patient
Behaviour	health care workers, clinical	expectations and responsibility
Change	commissioning groups, information	Focus groups
	prescription service, media	<u>Press releases</u> – hold events to get own message out, coupled with social media
	Everyone from infected individuals to	Crowdfunding
Novel	companies.	Patient involvement/sponsorship
Therapeutics	The main issue is funding and the	Innovative approaches to shortening regulatory process eg. Animal models are
	hurdles such as patient costs	expensive and not very good. Toxicology and pharmacokinetics are also expensive.
Modelling		
and	Patients, hospitals, farmers/	
Infection	veterinarians, pharmaceuticals	Acquire data, case studies to understand transmission
Control		